HomeALTME • EPA
add
TME Pharma NV
Previous close
€0.067
Day range
€0.070 - €0.077
Year range
€0.060 - €0.26
Market cap
6.58M EUR
Avg Volume
206.28K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 9.50K | 11.76% |
Operating expense | 1.27M | -12.11% |
Net income | -1.24M | 19.60% |
Net profit margin | -13.02K | 28.06% |
Earnings per share | — | — |
EBITDA | -1.26M | 12.07% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.24M | 44.54% |
Total assets | 3.41M | 36.73% |
Total liabilities | 1.79M | -35.66% |
Total equity | 1.61M | — |
Shares outstanding | 94.11M | — |
Price to book | 3.33 | — |
Return on assets | -92.52% | — |
Return on capital | -195.24% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -1.24M | 19.60% |
Cash from operations | -949.50K | 15.26% |
Cash from investing | -6.50K | — |
Cash from financing | 1.23M | 66.53% |
Net change in cash | 268.50K | 170.38% |
Free cash flow | -738.62K | 3.49% |
About
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Founded
1997
Website
Employees
12
